Double-boosted protease inhibitors (PIs) are under investigation for the treatment of patients who are unable to take nucleoside reverse transcriptase inhibitors because of cross-resistance and/or intolerance. Evidence of synergistic inhibition of wild-type HIV has been reported for saquinavir with atazanavir or lopinavir.
Methods
We investigated the activity of these two combinations against a panel of six site-directed mutant HIV-1 strains and 14 clinically derived recombinant HIV-1 strains presenting a range of PI-resistance profiles.
Results
No evidence of synergy was observed against wild-type virus for either combination. The combination of saquinavir and lopinavir showed evidence of synergy against four viruses displaying high-level resistance to lopinavir and low-level resistance to saquinavir. Similarly, evidence of synergy between saquinavir and atazanavir was only observed in two viruses which were more susceptible to saquinavir than to atazanavir.
Conclusions
We hypothesize that differences between the PIs in intracellular protein-binding behaviour or inhibition of drug transporters (P glycoprotein, MDR1 and MDR2) could result in intracellular levels of saquinavir being increased by co-administration with lopinavir or atazanavir. The effect of this increase would be masked in cases involving viruses that were susceptible to atazanavir or lopinavir. In virus resistant to lopinavir or atazanavir but susceptible to saquinavir, the majority of the antiviral effect is due to saquinavir; thus even small increases in intracellular concentration could significantly increase virus inhibition. These results confirm that in vitro synergy can be observed between PIs and suggest that the degree of synergy observed might depend on the resistance profile of the virus.
References
1.
Van HeeswijkR.P., VeldkampA., MulderJ.W.Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.Antivir Ther2001; 6: 201–229.
2.
MoyleG.J., BackD.Principles and practice of HIV-protease inhibitor pharmacoenhancement.HIV Med2001; 2: 105–113.
3.
CahnP.E., GatellJ.M., SquiresK.Atazanavir - a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.J Int Assoc Physicians AIDS Care (Chic Ill)2004; 3: 92–98.
4.
BoffitoM., DickinsonL., HillA.Steady-state pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.J Acquir Immune Defic Syndr2004; 37: 1376–1384.
5.
BoffitoM., KurowskiM., KruseG.Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.AIDS2004; 18: 1291–1297.
6.
StephanC., HentigN., KourbetiI.Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.AIDS2004; 18: 503–508.
7.
JohnsonV.A., Brun-VezinetF., ClotetB.Update of the Drug Resistance Mutations in HIV-1: 2005.Top HIV Med2005; 13: 51–57.
8.
KempfD.J., IsaacsonJ.D., KingM.S.Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.J Virol2001; 75: 7462–7469.
9.
HellingerJ., CohenC., MorrisA.Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients.HIV Clin Trials2005; 6: 107–117.
10.
KnechtenH., BraunP., WeismannF., EhretR., HoehnC.Switching from a non PI-containing regimen to saquinavir and lopinavir in therapy-experienced HIV-1–infected patients: a 48 weeks follow up.XV International AIDS Conference. Bangkok, Thailand, 11–16 July 2004. Abstract TuPe B4573.
11.
StaszewskiS., DauerB., CarlebachA.The LOPSAQ salvage study: 48 week analysis of the full cohort treated with lopinavir plus saquinavir without any additional anti-retroviral therapy.XV International AIDS Conference. Bangkok, Thailand, 11–16 July 2004. Abstract B10840.
12.
GongY.F., RobinsonB.S., RoseR.E.In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.Antimicrob Agents Chemother2000; 44: 2319–2326.
13.
FordJ., BoffitoM., WildfireA.The intracellular and plasma pharmacokinetics of saquinavir, atazanavir and ritonavir 1600/1200/100mg administered once daily in HIV-infected patients.7th International Conference on Drug Therapy in HIV infection. Glasgow, UK, 14–18 November 2004. Abstract PL6.3b.
14.
Von HentigN., MuellerA., HaberiA.The ATSAQ-1 cohort study: pharmacokinetic interactions of atazanavir and saquinavir in a ritonavir-boosted protease inhibitor therapy regimen. XV International AIDS conference. Bangkok, Thailand. 11–16 July 2004. Abstract WeOrB1235.
15.
PatickA.K., BoritzkiT.J., BloomL.A.Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.Antimicrob Agents Chemother1997; 41: 2159–64.
16.
TremblayC., MerrillD.P., ChouT.C., HirschM.S.Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates.J Acquir Immune Defic Syndr1999; 22: 430–436.
17.
DeminieC.A., BechtoldC.M., StockD.Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication.Antimicrob Agents Chemother1996; 40: 1346–1351.
18.
RobinsonB.S., RiccardiK.A., GongY.F.BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.Antimicrob Agents Chemother2000; 44: 2093–2099.
19.
MollaA., MoH., VasavanondaS.In vitro antiviral interaction of lopinavir with other protease inhibitors.Antimicrob Agents Chemother2002; 46: 2249–2253.
20.
CharneauP., MirambeauG., RouxP., PaulousS., BucH., ClavelF.HIV-1 reverse transcription. A termination step at the center of the genome.J Mol Biol1994; 241: 651–662.
21.
MammanoF., TrouplinV., ZennouV., ClavelF.Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug.J Virol2000; 74: 8524–8531.
22.
ChouT.C., TalalayP.Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.Adv Enzyme Regul1984; 22: 27–55.
23.
Belen'kiiM.S., SchinaziR.F.Multiple drug effect analysis with confidence interval.Antiviral Res1994; 25: 1–11.
24.
NascimbeniM., LamotteC., PeytavinG., FarinottiR., ClavelF.Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture.Antimicrob Agents Chemother1999; 43: 2629–2634.
25.
SrinivasR.V., MiddlemasD., FlynnP., FridlandA.Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters.Antimicrob Agents Chemother1998; 42: 3157–3162.
26.
JonesK., BrayP.G., KhooS.H.P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?AIDS2001; 15: 1353–1358.
27.
OlsonD.P., ScaddenD.T., D'aquilaR.T., De PasqualeM. P.. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).AIDS2002; 16: 1743–1747.
28.
HuismanM.T., SmitJ.W., WiltshireH.R., HoetelmansR.M., BeijnenJ.H., SchinkelA.H.P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.Mol Pharmacol2001; 59: 806–813.
